TY  - JOUR
A1  - Albinger, Nawid
A1  - Hartmann, Jessica
A1  - Ullrich, Evelyn
T1  - Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
T2  - Gene therapy
N2  - Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany.
KW  - Cancer
KW  - Immunotherapy
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/75078
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-750786
SN  - 1476-5462
N1  - The laboratory of EU has been supported by the FCI and DKTK (to EU), by the DFG (CRC/SFB 1292 and IRTG; to EU and NA), by the German Cancer Aid (to EU), the “Alfred & Angelika Gutermuth-Stiftung” (to EU), and by “Menschen für Kinder e.V.” (to EU). Open Access funding enabled and organized by Projekt DEAL.
VL  - 28
IS  - 9
SP  - 513
EP  - 527
PB  - Nature Publ. Group
CY  - London
ER  -